Trimurthi Share News - Latest Updates, Live News & More

Latest news about Trimurthi

Novelix Pharmaceuticals Reports Share Acquisition Under SEBI Regulation 29 Dec 26, 2025

Sesha Sai Nikhil Chintalapati acquired 4,92,000 equity shares in Novelix Pharmaceuticals Limited through preferential allotment on December 24, 2025, increasing his shareholding from 3.10% to 5.78%. The acquisition was disclosed under SEBI Regulation 29(1) requirements, with the company's equity capital standing at ₹17.21 crores comprising 17,215,000 shares. The disclosure also identifies DM Fincon Services LLP as a person acting in concert, maintaining their existing 20,000 share position.

Novelix Pharmaceuticals Allots 10.74 Lakh Equity Shares Upon Warrant Conversion Dec 24, 2025

Novelix Pharmaceuticals Signs 5-Year Lab Lease Deal at Genome Valley Dec 21, 2025

Novelix Pharmaceuticals Issues EGM Notice for ₹15 Crore Preferential Allotment Dec 11, 2025

Trimurthi Closes Trading Window Ahead of Fund-Raising Discussion Dec 08, 2025

More news about Trimurthi

14Nov 25

Trimurthi Reports Robust Q2 FY2026 Results with Net Profit of Rs 52.47 Crore

Trimurthi, an active pharmaceutical ingredients manufacturer and trader, announced unaudited financial results for Q2 FY2026. The company's total income rose to Rs 3,639.14 crore from Rs 387.37 crore in Q2 FY2025. Net profit increased to Rs 52.47 crore from Rs 12.95 crore. Half-year total income stood at Rs 5,874.26 crore with a net profit of Rs 64.03 crore. The company's balance sheet showed total assets of Rs 7,180.33 crore and total equity of Rs 2,560.96 crore. Ms. Monam Kapoor resigned as Independent Non-Executive Director.

23Oct 25

Trimurthi Appoints New Director and Allots 16.61 Lakh Equity Shares

Trimurthi's Board approved two key actions on October 23, 2025. Ms. Sridevi Belide, an MBBS holder related to the promoter group, was appointed as Additional Non-Executive Non-Independent Director. The company allotted 16,61,000 equity shares at Rs. 20 per share, raising Rs. 3.32 crore from 19 investors. This allotment, part of a larger warrant conversion, increased the paid-up equity capital from Rs. 14.48 crore to Rs. 16.14 crore, with total equity shares rising from 1.44 crore to 1.61 crore.

16Oct 25

Novelix Pharmaceuticals Partners with German Research Institute for Astaxanthin Production

Trimurthi has formed a technology transfer partnership with GMBU e.V., a German research institution, to advance large-scale production of Astaxanthin. The collaboration will take place at Novelix's laboratories in Hyderabad, India. GMBU e.V. will provide proprietary technology for cultivating Haematococcus pluvialis, while Novelix will offer financial and infrastructural support. Novelix plans to establish a GMP-certified production facility in Hyderabad, targeting markets in Europe, North America, and India. Astaxanthin, known for its strong antioxidant properties, has potential applications in various health areas including anti-diabetic, anti-inflammatory, neuroprotective, cardiovascular, ocular, and dermatological treatments.

21Sept 25

Novelix Pharmaceuticals Appoints New Directors and Secretarial Auditor

Trimurthi Limited, a Hyderabad-based pharmaceutical company, held its 31st Annual General Meeting on September 19, 2025. The company appointed two new directors: Mr. Gattu Gnana Prakash as Non-Executive Non-Independent Director and Ms. Mayuri Baidya as Non-Executive Independent Director. M/s Khushbu Kanwar & Co. was appointed as the Secretarial Auditor for a five-year term. All resolutions, including new appointments and corporate actions, were passed with overwhelming majority. Other approved actions include adopting financial statements, re-appointing a director, increasing borrowing limits, and authorizing various financial transactions.

11Aug 25

Novelis Reports 36% Drop in Q1 Net Income Despite 13% Sales Growth

Trimurthi, a Hindalco Industries subsidiary, reported mixed Q1 financial results. Net sales increased 13% to $4.70 billion, while net income fell 36% to $96.00 million. Rolled product shipments grew 1% to 963 kilotonnes. Adjusted EBITDA decreased 17% to $416.00 million, but operating cash flow improved 42% to $105.00 million. Higher aluminum prices boosted sales, but profitability was impacted by restructuring charges, higher scrap prices, unfavorable product mix, and negative tariff effects. Capital expenditures totaled $386.00 million, mainly for the new Bay Minette, Alabama plant. The company maintained strong liquidity at $3.00 billion with a net leverage ratio of 3.2x. CEO Steve Fisher noted strong demand for beverage packaging amid headwinds from higher scrap prices.